Group 1 - The core viewpoint of the article indicates that Huiyu Pharmaceutical expects a significant net loss for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-on-year decline of 108.91% to 107.38% [1] - The primary reason for this performance change is attributed to the fair value loss of 173 million yuan due to fluctuations in the stock price of its invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the HKEX 18A listing standard [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has announced an expected net loss for the fiscal year 2025, projecting a loss between 24 million to 29 million yuan [1] Financial Performance - The company anticipates a net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, to be between 78 million to 93 million yuan for the fiscal year 2025 [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has disclosed an expected net loss for the fiscal year 2025, projecting a loss between 24 million to 29 million yuan for the year [1] Financial Performance - The company anticipates a net profit attributable to the parent company, excluding non-recurring gains and losses, ranging from 78 million to 93 million yuan for the fiscal year 2025 [1]

Revenue Projections - The company expects 2025 annual revenue to be between 960 million and 1.09 billion yuan, representing a year-on-year decline of 12.28% to 0.40%[4]. - The projected net loss attributable to shareholders for 2025 is estimated to be between 29 million and 24 million yuan, a year-on-year decline of 108.91% to 107.38%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 78 million and 93 million yuan, showing a year-on-year decline of 15.33% to a growth of 0.96%[4]. Previous Year Performance - The previous year's net profit attributable to shareholders was 325.39 million yuan, with a total profit of 349.70 million yuan[7]. - The company reported earnings per share of 0.77 yuan for the previous year[8]. Performance Change Factors - The main reason for the performance change is the fair value loss of 173 million yuan due to the stock price fluctuation of the invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd.[9]. Financial Data and Audit - The financial data in the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the finance department[5]. - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast as of the announcement date[10]. - The final and accurate financial data will be disclosed in the audited annual report for 2025[11]. Investment Risks - Investors are advised to pay attention to investment risks due to the potential significant impact of stock price fluctuations on the company's financial statements[11].

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a net loss attributable to shareholders of the parent company for the fiscal year 2025, ranging from a loss of 29 million yuan to a loss of 24 million yuan, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 78 million yuan and 93 million yuan for 2025, which indicates a year-on-year change of a decline of 15.33% to an increase of 0.96% compared to the previous year [1] Investment Impact - The company's invested enterprise, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is set to be listed on the Hong Kong Stock Exchange under the 18A listing standard on August 20, 2024, with the stock code 02410.HK [1] - The fair value change loss of 173 million yuan during the reporting period was influenced by the stock price fluctuations of the invested enterprise [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a significant net loss for the fiscal year 2025, indicating a challenging financial outlook for the company [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company to range from a loss of 29 million yuan to a loss of 24 million yuan for 2025, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 78 million yuan and 93 million yuan, reflecting a year-on-year change of a decrease of 15.33% to an increase of 0.96% [1] Investment Impact - The company’s investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the stock code 02410.HK [1] - The fair value change loss due to the fluctuation in the stock price of the invested enterprise during the reporting period amounts to 173 million yuan [1]

Core Viewpoint - The announcement reveals that Huang Qianyi, a major shareholder of Huili Pharmaceutical, will passively reduce his shareholding due to a court's enforcement ruling, which mandates the forced sale of 1,300,000 shares [1][2] Group 1: Shareholder Reduction Plan - Huang Qianyi plans to reduce his holdings from February 3, 2026, to May 3, 2026, through centralized bidding, with a potential reduction of up to 1,300,000 shares, representing 0% to 0.307% of the company's total share capital [1] - The reduction is a result of judicial enforcement, and the shares involved are all unrestricted circulating shares [1] Group 2: Shareholder Information - As of the announcement date, Huang Qianyi holds 27,219,439 shares, accounting for 6.426% of Huili Pharmaceutical's total share capital [1] - Huang Qianyi is identified as the second-largest shareholder of Huili Pharmaceutical [2] Group 3: Company Background - Huili Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [2] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs [3] - The company plans to use the raised funds for the construction of an EU-standard injection production base and an innovative drug research institute, as well as to supplement working capital [3]

自愿披露HYP-6589片联合用药 获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥医药科技有限公司（以 下简称"汇宇海玥"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，化学创新药 HYP-6589片（项目研发代号为"HY-0006"）用于开展与奥希替尼联合治疗靶点驱动基因阳性的晚期非小 细胞肺癌的临床试验获得批准。现将相关情况公告如下： 一、药品基本情况 药品名称：HYP-6589片 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688553 证券简称：汇宇制药 公告编号：2026-005 四川汇宇制药股份有限公司 注册分类：化学药品1类创新药 申请事项：境内生产药品注册临床试验 受理号：CXHL2501288；CXHL2501289； 适应症：拟用于与奥希替尼联合治疗靶点驱动基因阳性的晚期非小细胞肺癌。 申请人：四川汇宇海玥医药科技有限公司 审批结论：根据《中华人民共和国药品管理法》及 ...

Group 1 - The core announcement is that Huayu Pharmaceutical's wholly-owned subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the innovative chemical drug HYP-6589 tablets, which is intended for use in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [2] Group 2 - The clinical trial approval is a significant step for the company in advancing its research and development efforts in oncology [2] - HYP-6589, also referred to by its research and development code "HY-0006," represents a potential new treatment option in the competitive oncology market [2] - The approval highlights the company's commitment to developing innovative therapies for serious health conditions [2]

每经AI快讯，汇宇制药1月28日晚间发布公告称，近日，四川汇宇制药股份有限公司全资子公司四川汇 宇海玥医药科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，化学创新 药HYP-6589片用于开展与奥希替尼联合治疗靶点驱动基因阳性的晚期非小细胞肺癌的临床试验获得批 准。 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王晓波） ...